Yu Taniguchi

2.1k total citations
72 papers, 1.3k citations indexed

About

Yu Taniguchi is a scholar working on Pulmonary and Respiratory Medicine, Cardiology and Cardiovascular Medicine and Surgery. According to data from OpenAlex, Yu Taniguchi has authored 72 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 56 papers in Pulmonary and Respiratory Medicine, 46 papers in Cardiology and Cardiovascular Medicine and 19 papers in Surgery. Recurrent topics in Yu Taniguchi's work include Pulmonary Hypertension Research and Treatments (50 papers), Cardiovascular Function and Risk Factors (19 papers) and Coronary Interventions and Diagnostics (16 papers). Yu Taniguchi is often cited by papers focused on Pulmonary Hypertension Research and Treatments (50 papers), Cardiovascular Function and Risk Factors (19 papers) and Coronary Interventions and Diagnostics (16 papers). Yu Taniguchi collaborates with scholars based in Japan, France and Canada. Yu Taniguchi's co-authors include Hiroto Kinutani, Ken‐ichi Hirata, Hiromasa Otake, Gérald Simonneau, Toshiro Shinke, Xavier Jaïs, Marc Humbert, Noriaki Emoto, Olivier Sitbon and Tsuyoshi Osue and has published in prestigious journals such as Circulation, Journal of the American College of Cardiology and PLoS ONE.

In The Last Decade

Yu Taniguchi

64 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yu Taniguchi Japan 18 940 914 420 209 178 72 1.3k
Hilary M. DuBrock United States 16 752 0.8× 472 0.5× 347 0.8× 127 0.6× 30 0.2× 81 1.1k
Nikolaos Kakouros United States 14 143 0.2× 729 0.8× 212 0.5× 21 0.1× 119 0.7× 71 998
Kentaro Ejiri Japan 17 330 0.4× 422 0.5× 307 0.7× 78 0.4× 57 0.3× 72 970
Steffen Brucks United States 13 257 0.3× 619 0.7× 344 0.8× 15 0.1× 147 0.8× 17 916
Najmeddine Echahidi France 11 185 0.2× 1.1k 1.2× 277 0.7× 18 0.1× 226 1.3× 22 1.3k
Laurent Leborgne France 17 353 0.4× 769 0.8× 760 1.8× 30 0.1× 428 2.4× 68 1.2k
Esmeray Acartürk Türkiye 17 142 0.2× 562 0.6× 221 0.5× 35 0.2× 71 0.4× 59 829
Won-Heum Shim South Korea 20 584 0.6× 496 0.5× 600 1.4× 7 0.0× 154 0.9× 51 1.1k
Jun Kwan South Korea 20 86 0.1× 1.0k 1.1× 517 1.2× 99 0.5× 292 1.6× 78 1.3k
Alexander Stefanidis Greece 8 310 0.3× 461 0.5× 199 0.5× 60 0.3× 93 0.5× 13 693

Countries citing papers authored by Yu Taniguchi

Since Specialization
Citations

This map shows the geographic impact of Yu Taniguchi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yu Taniguchi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yu Taniguchi more than expected).

Fields of papers citing papers by Yu Taniguchi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yu Taniguchi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yu Taniguchi. The network helps show where Yu Taniguchi may publish in the future.

Co-authorship network of co-authors of Yu Taniguchi

This figure shows the co-authorship network connecting the top 25 collaborators of Yu Taniguchi. A scholar is included among the top collaborators of Yu Taniguchi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yu Taniguchi. Yu Taniguchi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hattori, Yasuhiro, Nobuko Ohshima, Yu Taniguchi, et al.. (2025). 22O Development of anti-CD38-CAR allogeneic γδ T cells as an off-the-shelf use for myeloma. ESMO Open. 10. 104179–104179.
2.
Ogo, Takeshi, Toshiro Shinke, Nobutaka Ikeda, et al.. (2025). Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension: A Nationwide Prospective Multicenter Registry in Japan (J-BPA). Circulation Cardiovascular Interventions. 18(12). e016172–e016172.
3.
Yanaka, Kenichi, Kazuhiko Nakayama, Yu Taniguchi, et al.. (2025). Difference in efficacy between pulmonary endarterectomy and balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension. BMC Pulmonary Medicine. 25(1). 376–376.
4.
5.
Sakao, Seiichiro, Yasuhiro Kondoh, Hideyuki Kinoshita, et al.. (2024). Efficacy, safety, and pharmacokinetics of inhaled treprostinil in Japanese patients with pulmonary hypertension associated with interstitial lung disease. Respiratory Investigation. 62(6). 980–986. 3 indexed citations
6.
7.
8.
9.
Fujii, Hiroyuki, Yu Taniguchi, Yoichiro Matsuoka, et al.. (2023). Efficacy and Safety of Balloon Pulmonary Angioplasty for Patients With Chronic Thromboembolic Pulmonary Hypertension and Comorbid Chronic Obstructive Pulmonary Disease. Journal of the American Heart Association. 12(3). e026466–e026466. 1 indexed citations
10.
Tamura, Yuichi, et al.. (2023). Current clinical understanding and effectiveness of portopulmonary hypertension treatment. Frontiers in Medicine. 10. 1142836–1142836. 4 indexed citations
11.
12.
Matsuoka, Yoichiro, Yu Taniguchi, Yasunori Tsuboi, et al.. (2021). Assessment of oxygenation after balloon pulmonary angioplasty for patients with inoperable chronic thromboembolic pulmonary hypertension. International Journal of Cardiology. 333. 188–194. 8 indexed citations
13.
Ferrari, Émile, et al.. (2020). PULMONARY ANGIOPLASTY WITHOUT ANTICOAGULANTS MAY REDUCE THE RATE OF HEMOPTYSIS AND MAKE THE PROCEDURE SAFER. Journal of the American College of Cardiology. 75(11). 2100–2100. 1 indexed citations
14.
Taniguchi, Yu, et al.. (2019). “Anagrelide‐induced pulmonary arterial hypertension”: a rare case of drug‐induced pulmonary arterial hypertension. Pulmonary Circulation. 9(4). 1–3. 2 indexed citations
15.
Taniguchi, Yu, Xavier Jaïs, Mitja Jevnikar, et al.. (2019). Predictors of survival in patients with not-operated chronic thromboembolic pulmonary hypertension. The Journal of Heart and Lung Transplantation. 38(8). 833–842. 51 indexed citations
16.
Amsallem, Myriam, Julien Guihaire, Jennifer Arthur Ataam, et al.. (2018). Impact of the initiation of balloon pulmonary angioplasty program on referral of patients with chronic thromboembolic pulmonary hypertension to surgery. The Journal of Heart and Lung Transplantation. 37(9). 1102–1110. 11 indexed citations
17.
Amsallem, Myriam, Julien Guihaire, Jennifer Arthur Ataam, et al.. (2018). IMPACT OF INITIATION OF BALLOON PULMONARY ANGIOPLASTY PROGRAM ON REFERRAL OF PATIENTS WITH CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION TO SURGERY. Journal of the American College of Cardiology. 71(11). A1958–A1958. 1 indexed citations
18.
Weatherald, Jason, Athénaïs Boucly, D. S. Chemla, et al.. (2017). Prognostic Value of Follow-Up Hemodynamic Variables After Initial Management in Pulmonary Arterial Hypertension. Circulation. 137(7). 693–704. 141 indexed citations
19.
Inoue, Takumi, Toshiro Shinke, Hiromasa Otake, et al.. (2014). Impact of strut–vessel distance and underlying plaque type on the resolution of acute strut malapposition: serial optimal coherence tomography analysis after everolimus-eluting stent implantation. International journal of cardiac imaging. 30(5). 857–865. 14 indexed citations
20.
Taniguchi, Yu, Noriaki Emoto, Hiroto Kinutani, et al.. (2013). TCT-102 Efficacy and Safety of Balloon Pulmonary Angioplasty for Non-operable Chronic Thromboembolic Pulmonary Hypertension in Comparison to Pulmonary Endarterectomy for Operable Patients. Journal of the American College of Cardiology. 62(18). B33–B33. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hilary M. DuBrock Breakdown of academic impact, for papers by Nikolaos Kakouros Breakdown of academic impact, for papers by Kentaro Ejiri Breakdown of academic impact, for papers by Steffen Brucks Breakdown of academic impact, for papers by Najmeddine Echahidi Breakdown of academic impact, for papers by Laurent Leborgne Breakdown of academic impact, for papers by Esmeray Acartürk Breakdown of academic impact, for papers by Won-Heum Shim Breakdown of academic impact, for papers by Jun Kwan Breakdown of academic impact, for papers by Alexander Stefanidis
Rankless by CCL
2026